Background: Extant research on cognitive functioning in treatment-resistant schizophrenia
(TRS) is limited and of poor quality. Cognitive impairments in patients with schizophrenia …

Clozapine is the only medication found to be effective for patients with treatment resistant
schizophrenia-spectrum disorders (TRS) and its prescription patterns may impact on their …

Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised,
complication of many types of pharmacological treatment. While there is a large body of …

Currently available antipsychotics provide only modest benefit in managing the cognitive
and negative symptoms of schizophrenia even though these symptoms are often the most …

Objective The clozapine/N-desmethylclozapine (NDMC) ratio is proposed to be used as a
predictor of cognitive performance in clozapine-treated patients, as its principal metabolite …

Although previous findings identified an association between C-reactive protein (CRP)
levels, and impaired cognitive functions in patients with schizophrenia (SZ), little is currently …

Clozapine (CLZ) demonstrates a unique clinical efficacy relative to other antipsychotic
drugs. Previous work has linked the plasma ratio of CLZ and its major metabolite, N …

Aproximadamente el 30% de los pacientes con diagnóstico de esquizofrenia no responden
al tratamiento con antipsicóticos produciendo una importante carga de la enfermedad. La …

The functional status of an individual with schizophrenia is the defining factor in their quality
of life and is closely associated with cognitive abilities, which are impaired in individuals with …

Post-traumatic stress disorder (PTSD) is a chronic illness defined as more than 1 month of
intrusion symptoms, avoidance, negative alterations in cognition and mood, and alterations …